↓ Skip to main content

TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases

Overview of attention for article published in Journal of Hematology & Oncology, May 2015
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (75th percentile)

Mentioned by

twitter
10 tweeters
facebook
1 Facebook page

Citations

dimensions_citation
86 Dimensions

Readers on

mendeley
75 Mendeley
citeulike
1 CiteULike
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases
Published in
Journal of Hematology & Oncology, May 2015
DOI 10.1186/s13045-015-0139-z
Pubmed ID
Authors

Chi Young Ok, Keyur P Patel, Guillermo Garcia-Manero, Mark J Routbort, Jie Peng, Guilin Tang, Maitrayee Goswami, Ken H Young, Rajesh Singh, L Jeffrey Medeiros, Hagop M Kantarjian, Rajyalakshmi Luthra, Sa A Wang

Abstract

TP53 mutation is more prevalent in therapy-related myeloid neoplasms (t-MN) than their de novo counterparts; however, the pattern of mutations involving TP53 gene in t-MN versus de novo diseases is largely unknown. We collected 108 consecutive patients with therapy-related myelodysplastic syndrome (t-MDS)/acute myeloid leukemia (t-AML). Clinical, hematological, and cytogenetic data were collected by searching the electronic medical record. TP53 sequencing was performed in all patients using a clinically validated next-generation sequencing-based gene panel assay. A previously published patient cohort consisting of 428 patients with de novo MDS/AML was included for comparison. We assessed 108 patients with t-MN, in which 40 patients (37%) had TP53 mutations. The mutation frequency was similar between t-MDS and t-AML; but significantly higher than de novo MDS/AML (62/428 patients, 14.5%) (p < 0.0001). TP53 mutations in t-MN were mainly clustered in DNA-binding domains, with an allelic frequency of 37.0% (range, 7.1 to 98.8). Most mutations involved single nucleotide changes, of which, transitions (65.9%) were more common than transversions (34.1%). Missense mutations were the most frequent, followed by frameshift and nonsense mutations. This TP53 mutation pattern was strikingly similar to that observed in de novo MDS/AML. TP53 mutations in t-MN were associated with a complex karyotype (p < 0.0001), a higher number of chromosomal abnormalities (p < 0.0001), and an inferior overall survival in affected patients (6.1 vs 14.1 months) by univariate (p < 0.0001) and multivariate analyses (p = 0.0020). Our findings support the recent notion that heterozygous TP53 mutation may be a function of normal aging and that mutated cells are subject to selection upon exposure to cytotoxic therapy. t-MN carrying TP53 mutation have an aggressive clinical course independent of other confounding factors.

Twitter Demographics

The data shown below were collected from the profiles of 10 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 75 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Denmark 1 1%
Canada 1 1%
Unknown 73 97%

Demographic breakdown

Readers by professional status Count As %
Researcher 14 19%
Student > Bachelor 9 12%
Student > Ph. D. Student 8 11%
Other 6 8%
Student > Master 5 7%
Other 17 23%
Unknown 16 21%
Readers by discipline Count As %
Medicine and Dentistry 23 31%
Biochemistry, Genetics and Molecular Biology 14 19%
Agricultural and Biological Sciences 8 11%
Pharmacology, Toxicology and Pharmaceutical Science 3 4%
Unspecified 1 1%
Other 5 7%
Unknown 21 28%

Attention Score in Context

This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 March 2022.
All research outputs
#5,180,018
of 21,377,679 outputs
Outputs from Journal of Hematology & Oncology
#318
of 1,101 outputs
Outputs of similar age
#60,547
of 248,646 outputs
Outputs of similar age from Journal of Hematology & Oncology
#1
of 1 outputs
Altmetric has tracked 21,377,679 research outputs across all sources so far. Compared to these this one has done well and is in the 75th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,101 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.9. This one has gotten more attention than average, scoring higher than 71% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 248,646 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 75% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them